专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06849619B2 Substituted pyridoindoles as serotonin agonists and antagonists 有权
标题翻译：取代的吡啶并吲哚作为血清素激动剂和拮抗剂
公开(公告)号：US06849619B2
公开(公告)日：2005-02-01
申请号：US10784064
申请日：2004-02-20
申请人： Albert J. Robichaud , John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
发明人： Albert J. Robichaud , John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
IPC分类号： C07D471/16 , C07D498/16 , C07D513/16 , A61K31/33 , A61K31/55 , C07D223/14 , C07D245/00 , C07D267/02
CPC分类号： C07D471/16 , C07D498/16 , C07D513/16
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6，R 7，R 8，R <9>，X，b，k和n，这里描述虚线。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

2. 发明授权

US06699852B2 Substituted pyridoindoles as serotonin agonists and antagonists 有权
标题翻译：取代的吡啶并吲哚作为血清素激动剂和拮抗剂
公开(公告)号：US06699852B2
公开(公告)日：2004-03-02
申请号：US10026611
申请日：2001-12-19
申请人： Albert Robichaud , John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
发明人： Albert Robichaud , John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
IPC分类号： A61K3133
CPC分类号： C07D471/16 , C07D498/16 , C07D513/16
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6，R 7，R 8，R <9>，X，b，k和n，这里描述虚线。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

3. 发明授权

US06777406B2 Substituted pyrroloquinolines and pyridoquinolines as serotinin agonists and antagonists 有权
标题翻译：取代的吡咯并喹啉和吡啶并喹啉作为血清素激动剂和拮抗剂
公开(公告)号：US06777406B2
公开(公告)日：2004-08-17
申请号：US10026993
申请日：2001-12-19
申请人： John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
发明人： John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
IPC分类号： C07D471106
CPC分类号： C07D471/16 , C07D498/16
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein is R1, R6a, R6b, R7, R8, R9, X, b, m, and n are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 6a，R 6b，R 7，R 8， R 9，X，b，m和n在本文中描述。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

4. 发明授权

US06548493B1 Substituted heterocycle fused gamma-carbolines 有权
公开(公告)号：US06548493B1
公开(公告)日：2003-04-15
申请号：US09594008
申请日：2000-06-15
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. B. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. B. Calvello , David M. Zawrotny
IPC分类号： C07D51316
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

5. 发明授权

US07238690B2 Substituted heterocycle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合的γ-咔啉
公开(公告)号：US07238690B2
公开(公告)日：2007-07-03
申请号：US11375935
申请日：2006-03-15
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
IPC分类号： C07D491/16 , A61K31/5383
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
摘要翻译：本发明涉及可用于治疗由结构式（I）或其药学上可接受的盐形式表示的成瘾行为和睡眠障碍的化合物，其中R 1，R 5， R 6a，R 6b，R 7，R 8，R 9， X，b，k，m和n，这里描述虚线。用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括上瘾行为和睡眠障碍。

6. 再颁专利

USRE39679E1 Substituted heterocycle fused gamma-carbolines 有权
公开(公告)号：USRE39679E1
公开(公告)日：2007-06-05
申请号：US11356423
申请日：2006-02-16
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
IPC分类号： C07D267/22 , C07D281/18 , C07D267/02 , C07D279/00 , C07D265/34
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

7. 发明授权

US07081455B2 Substituted heterocycle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合的γ-咔啉
公开(公告)号：US07081455B2
公开(公告)日：2006-07-25
申请号：US10786935
申请日：2004-02-25
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
IPC分类号： A61P25/00
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
摘要翻译：本发明涉及通过施用由结构式（I）表示的化合物或其药学上可接受的盐形式来治疗成瘾行为和睡眠障碍的方法，其中R 1，R 5， R 6a，R 6b，R 7，R 8，R 9，R 9， >，X，b，k，m和n，这里描述虚线。用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括上瘾行为和睡眠障碍。

8. 发明授权

US06713471B1 Substituted heterocycle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合的γ-咔啉
公开(公告)号：US06713471B1
公开(公告)日：2004-03-30
申请号：US09594954
申请日：2000-06-15
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Simon Haydar , Wenting Chen , Christopher D. Mc Clung , Emilie J. B. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Simon Haydar , Wenting Chen , Christopher D. Mc Clung , Emilie J. B. Calvello , David M. Zawrotny
IPC分类号： C07D26722
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6a，R 6b，R 7，R 7， <8>，R 9，X，b，k，m和n，这里描述虚线。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

9. 发明授权

US06552017B1 Substituted heterocycle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合的γ-咔啉
公开(公告)号：US06552017B1
公开(公告)日：2003-04-22
申请号：US09595250
申请日：2000-06-15
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. Mc Clung , Emilie J. B. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. Mc Clung , Emilie J. B. Calvello , David M. Zawrotny
IPC分类号： C07D48700
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R1，R5，R6a，R6b，R7，R8，R9，X，b，k，m和n以及这里描述了虚线。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

10. 再颁专利

USRE39680E1 Substituted heterocycle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合的γ-咔啉
公开(公告)号：USRE39680E1
公开(公告)日：2007-06-05
申请号：US11356421
申请日：2006-02-16
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
IPC分类号： C07D487/00 , C07D243/00 , C07D491/00 , C07D241/36 , A61K31/55
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6， R 6b，R 6b，R 7，R 8，R 9，X，b，k， m和n，虚线在此描述。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式